Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Poly-l-Lactic Acid as a Regenerative Treatment for the Glucagon-like Peptide-1 Receptor Agonist User Population.

Franco J., Aguilera SB., Le JH., Brasater D., Nicodeme E., Meckfessel MH.

Narrative Review on Skin Aging, published in Dermatol Surg (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Dermatol Surg (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
42210881
DOI
10.1097/DSS.0000000000005171

Abstract (original English)

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) used for weight management have introduced unintended facial changes only partially addressed by conventional volumizing fillers. Evaluate the mechanistic rationale and clinical evidence supporting poly-l-lactic acid Sculptra (PLLA-SCA) as a biostimulatory and regenerative treatment for GLP-1 RA-associated facial changes. This narrative review synthesizes mechanistic and clinical data alongside expert opinion regarding PLLA-SCA for GLP-1 RA-driven weight loss, focusing on its biostimulatory and regenerative effects across skin layers. Poly-l-lactic acid Sculptra induces fibroblast recruitment and stimulates regeneration of collagen and elastin, and effects vasculature and adipose tissue, resulting in durable improvements in skin quality, elasticity, facial contour, and perceived age that persist for 2 years or longer. Clinical studies and real-world experiences demonstrate clinically meaningful corrections of midface and perioral volume loss, jawline contour, and radiance, including in patients with GLP-1 RA-related facial changes. Poly-l-lactic acid Sculptra may help address GLP-1 RA-associated facial atrophy by supporting long-term regeneration and restoration of facial definition, contour, and skin quality. The effects potentially extend across all 3 skin layers affected by the GLP-1 RA phenotype, including atrophy and

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansGlucagon-Like Peptide-1 Receptor AgonistsPolyestersCosmetic TechniquesSkin AgingFaceWeight LossRegenerationDermal Fillers

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research